PureTech Health PLC (PRTC) News
Filter PRTC News Items
PRTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PRTC News From Around the Web
Below are the latest news stories about PURETECH HEALTH PLC that investors may wish to consider to help them evaluate PRTC as an investment opportunity.
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AMLPureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia. “Fast Track designation is a process designed to streamline the development and accelerate the assessment of drugs that target serious conditions with unmet medical need,” the company stated. The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML a |
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)BOSTON, January 09, 2025--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) |
PureTech to Present at 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON, January 08, 2025--PureTech to present at 43rd annual J.P. Morgan Healthcare Conference. |
PureTech Appoints UBS as UK Corporate BrokerBOSTON, January 06, 2025--PureTech Appoints UBS as UK Corporate Broker. |
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis PatientsPureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The trial evaluated deupirfenidone at two doses three times a day (TID) over 26 weeks in IPF patients. Participants in the trial were randomized 1:1:1:1 to receive deupirfenidone 550 mg, deupirfenidone 825 mg, pirfenidone 801 mg (the FDA-approved dose), or placebo TID for 26 weeks, and had the option to e |
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b TrialBOSTON, December 16, 2024--PureTech’s Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial |
With 71% institutional ownership, PureTech Health plc (LON:PRTC) is a favorite amongst the big gunsKey Insights Institutions' substantial holdings in PureTech Health implies that they have significant influence over... |
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024BOSTON, December 11, 2024--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 |
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual MeetingBOSTON, December 09, 2024--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting |
FTSE 100 reshuffle sees Vistry kicked out and Games Workshop join the UK blue-chip indexVistry and Frasers are among the stocks that will be relegated from the FTSE 100, while Games Workshop will be added to the UK blue-chip index. |